(Q34215804)

31 July 2017

1 reference

title

Role of modelling and simulation in Phase I drug development (English)

1 reference

31 July 2017

L Aarons

1

1 reference

31 July 2017

M O Karlsson

2

1 reference

31 July 2017

F Mentré

3

1 reference

31 July 2017

F Rombout

4

1 reference

31 July 2017

J L Steimer

5

1 reference

31 July 2017

A van Peer

6

1 reference

31 July 2017

COST B15 Experts

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

European Journal of Pharmaceutical Sciences

31 July 2017

1 reference

31 July 2017

13

1 reference

31 July 2017

2

1 reference

31 July 2017

115-122

1 reference

Plasma concentration--effect relationships for felodipine: a meta analysis

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Structure-function relationship of recombinant follicle stimulating hormone (Puregon).

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Simulation of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Pharmacodynamic modelling. Application to new drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Estimating impossible curves using NONMEM.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Learning versus confirming in clinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Pharmacokinetic/pharmacodynamic modeling in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Population pharmacokinetics. A regulatory perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2801%2900096-3

7 January 2021

10.1016/S0928-0987(01)00096-3

Identifiers

DOI

1 reference

31 July 2017

1 reference